Congressional ‘Cures’ Debate Shifts To FDA Funding
This article was originally published in The Pink Sheet Daily
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
You may also be interested in...
Additional funding would arrive beginning in FY 2017 as House pushes bill to Senate.
Another user fee for the US drug agency could help pay for research of off-label uses, but lack of resources could be a regulatory problem.
HELP Committee chairman finally calls his package a companion to 21st Century Cures bill, but more work is necessary to bring it in line with the House legislation.